The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that stop ALS as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, as well as a multi-pronged approach to validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs. The Institute's unique, industrial-scale platform allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world’s largest ALS research center and the only non-profit biotechnology company with more than 30 professional scientists focused on a single disease indication. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry.

As a non-profit, we rely on the generosity of the ALS Community. Those that give more than $1,000 cumulative in a calendar year become members of the Leadership Giving Circle. Click here to learn more about giving, and to view the most recent membership listing.

What We Do

ALSTDI combines the passion and dedication of a nonprofit organization with the entrepreneurial and scientific spirit of a biotechnology company

• Our laboratory, the leading drug discovery program for ALS, bridges a critical research gap
• Our in-house expertise translates research into potential drug candidates by screening drugs in the SOD1 mouse model of ALS.
• Our scientific collaborations are designed to bring the most promising leads closer to patient use.
• We share emerging knowledge on the disease with patients, physicians, and researchers as quickly and comprehensively as possible.
• Every decision is made in the interest of finding effective treatments for people living with ALS.
• Our unique approach accelerates drug development for ALS.

In Our Lab

How You Can Help...